Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse MyelitisAmerican Journal of the Medical Sciences.  356:561-566. 2018
2018 14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic α-synucleinJournal of Neuroscience.  38:8211-8232. 2018
2017 Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathologyAnnals of Clinical and Translational Neurology.  4:466-477. 2017
2017 Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathiesMovement Disorders.  32:840. 2017
2016 CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.Neurology, Neuroimmunology and Neuroinflammation.  3:e266. 2016
2016 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shorteningHuman Molecular Genetics.  25:109-122. 2016
2015 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's diseaseNeuroscience.  307:73-82. 2015
2015 Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteinsNeurobiology of Disease.  79:1-13. 2015
2014 Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegenerationMovement Disorders.  29:306-306. 2014
2013 LRRK2 secretion in exosomes is regulated by 14-3-3Human Molecular Genetics.  22:4988-5000. 2013
2013 α-synuclein overexpression represses 14-3-3θ transcriptionJournal of Molecular Neuroscience.  51:1000-1009. 2013
2013 IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Neurodegenerative Disease Management.  3:123-131. 2013
2013 Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated MicePLoS ONE.  8. 2013
2012 Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's diseaseJournal of Neuroscience.  32:2142-2153. 2012
2011 14-3-3theta protects against neurotoxicity in a cellular parkinson's disease model through inhibition of the apoptotic factor BaxPLoS ONE.  6. 2011
2011 A neuroprotective role for angiogenin in models of Parkinson's diseaseJournal of Neurochemistry.  116:334-341. 2011
2011 Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's diseasePLoS ONE.  6. 2011
2010 Target validation: The Parkinson disease perspectiveDisease Models & Mechanisms.  3:259-262. 2010
2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's diseaseCell Death and Disease.  1. 2010
2009 Targets for neuroprotection in Parkinson's diseaseBBA - Molecular Basis of Disease.  1792:676-687. 2009
2009 Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: A cross-sectional studyNeuroepidemiology.  33:329-334. 2009
2008 Transcriptional dysregulation in a transgenic model of Parkinson diseaseNeurobiology of Disease.  29:515-528. 2008
2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Molecular Brain.  1:17. 2008
2000 Truncated and full-length TrkB receptors regulate distinct modes of dendritic growthNature Neuroscience.  3:342-349. 2000
1999 Subcellular localization of full-length and truncated Trk receptor isoforms in polarized neurons and epithelial cellsJournal of Neuroscience.  19:5823-5833. 1999

Chapter

Year Title Altmetric
2017 Neurodegenerative Disorders: Why Do We Need New Therapies?.  1-16. 2017
2011 Neuroprotective Therapies for Parkinson’s disease 2011

Principal Investigator On

  • 14-3-3 Phosphorylation in Parkinson’s Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2019 - 2024
  • Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by RETROPHIN, INC. 2019 - 2022
  • Southeastern Medical Scientist Symposium  awarded by National Institute of General Medical Sciences/NIH/DHHS 2019 - 2021
  • Regulation of Alpha Synuclein Release and Toxicity by Rab27b  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2020
  • Regulation of Cellular Release of Proteins in Parkinson's Neurodegeneration  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2020
  • Rab27b As A Potential Regulator of Alpha-Synuclein Spread  awarded by American Parkinson Disease Association 2018 - 2020
  • Clinical Trial Readiness for SCA 1 and SCA3  awarded by THE METHODIST HOSPITAL RESEARCH INSTITUTE 2018 - 2019
  • Rab27b as a Potential Regulator of Alpha-Synuclein Spread  awarded by American Parkinson Disease Association 2017 - 2019
  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2015 - 2018
  • 14-3-3 Regulation of Beta-Amyloid Toxicity  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2016
  • Effects of 14-3-3s on Alpha-Synuclein Release and Toxicity  awarded by American Parkinson Disease Association 2014 - 2016
  • 14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2014 - 2015
  • Effects of 14-3-3s on Alpha-Synuclein Release and Toxicity  awarded by American Parkinson Disease Association 2013 - 2014
  • Role of 14-3-3 Proteins in Alpha-Synuclein-Induced Neurotoxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2013
  • 14-3-3s as Regulators of LRRK2 Toxicity  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2011 - 2013
  • Effects of Coenzyme Q10 in PSP, A Multicenter, Randomized, Placebo-Controlled, Double Blind Study  awarded by LAHEY CLINIC, INC. 2011 - 2013
  • Education And Training

  • Doctor of Medicine, Duke University 2001
  • Massachusetts General Hospital, Residency 2005
  • Massachusetts General Hospital, Postdoctoral Fellowship 2006
  • Full Name

  • Talene Yacoubian